A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

Inclusion Criteria:

* Written informed consent obtained.
* Has ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 at the time of the randomisation.
* Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum.
* RAS status must have been determined (mutant or wild).
* Has at least one measurable metastatic lesion.
* No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.
* Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is allowed only if if it has been completed more than 6 months before start of study treatment.
* Patient is not a candidate for combination chemotherapy with irinotecan or oxaliplatin, or for curative resection of metastatic lesions.
* Is able to take medication orally (i.e., no feeding tube).
* Has adequate organ function.
* Coagulation parameters in normal limit (or in therapeutic limit for patients treated with anticoagulant drugs).
* Women of childbearing potential must have been tested negative in a serum pregnancy test. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of birth control. Women and female partners using hormonal contraceptive must also use a barrier method.

Exclusion Criteria:

* Is a pregnant or lactating female.
* Has certain serious illness or serious medical condition(s) as described in the protocol.
* Has had certain other recent treatment e.g. major surgery, field radiation, received investigational agent, within the specified time frames prior to randomisation.
* Has previously received Trifluridine/tipiracil or history of allergic reactions attributed to compounds of similar composition to Trifluridine/tipiracil or any of its excipients.
* Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
* Has contra-indication to bevacizumab or capecitabine.